Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells.

Clarke K, Young C, Liberante F, McMullin MF, Thompson A, Mills K.

Oncotarget. 2019 May 28;10(37):3462-3471. doi: 10.18632/oncotarget.26877. eCollection 2019 May 28.

2.

Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?

Stintzing S, Kemmerling R, Kiesslich T, Alinger B, Ocker M, Neureiter D.

J Biomed Biotechnol. 2011;2011:214143. doi: 10.1155/2011/214143. Epub 2011 May 15. Review.

3.

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.

Stahl M, Gore SD, Vey N, Prebet T.

Expert Opin Investig Drugs. 2016;25(3):307-17. doi: 10.1517/13543784.2016.1146251. Review.

PMID:
26807602
4.

Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.

Odenike OM, Alkan S, Sher D, Godwin JE, Huo D, Brandt SJ, Green M, Xie J, Zhang Y, Vesole DH, Stiff P, Wright J, Larson RA, Stock W.

Clin Cancer Res. 2008 Nov 1;14(21):7095-101. doi: 10.1158/1078-0432.CCR-08-1007.

5.

Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.

Luchenko VL, Litman T, Chakraborty AR, Heffner A, Devor C, Wilkerson J, Stein W, Robey RW, Bangiolo L, Levens D, Bates SE.

Mol Oncol. 2014 Dec;8(8):1379-92. doi: 10.1016/j.molonc.2014.05.001. Epub 2014 May 28.

6.

Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines.

Zhang C, Suo J, Katayama H, Wei Y, Garcia-Manero G, Hanash S.

Clin Proteomics. 2016 Jul 5;13:14. doi: 10.1186/s12014-016-9115-z. eCollection 2016.

7.

Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.

To KK, Polgar O, Huff LM, Morisaki K, Bates SE.

Mol Cancer Res. 2008 Jan;6(1):151-64. doi: 10.1158/1541-7786.MCR-07-0175.

8.

The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.

Murray-Stewart T, Woster PM, Casero RA Jr.

Amino Acids. 2014 Mar;46(3):585-94. doi: 10.1007/s00726-013-1485-1. Epub 2013 Mar 19.

9.

ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation.

Saika M, Inoue D, Nagase R, Sato N, Tsuchiya A, Yabushita T, Kitamura T, Goyama S.

Sci Rep. 2018 Oct 26;8(1):15873. doi: 10.1038/s41598-018-33881-2.

10.

Linking site-specific loss of histone acetylation to repression of gene expression by the mycotoxin ochratoxin A.

Limbeck E, Vanselow JT, Hofmann J, Schlosser A, Mally A.

Arch Toxicol. 2018 Feb;92(2):995-1014. doi: 10.1007/s00204-017-2107-6. Epub 2017 Nov 2.

PMID:
29098329
11.

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.

Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, Wu N, Panageas K, Wright JJ, Pandolfi PP, Nimer SD.

Clin Cancer Res. 2008 Feb 1;14(3):826-32. doi: 10.1158/1078-0432.CCR-07-0318.

12.

Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling.

Zhao S, Guo J, Zhao Y, Fei C, Zheng Q, Li X, Chang C.

Am J Transl Res. 2016 Jul 15;8(7):3169-78. eCollection 2016.

13.

Identification of repressive and active epigenetic marks and nuclear bodies in Entamoeba histolytica.

Lozano-Amado D, Herrera-Solorio AM, Valdés J, Alemán-Lazarini L, Almaraz-Barrera Mde J, Luna-Rivera E, Vargas M, Hernández-Rivas R.

Parasit Vectors. 2016 Jan 14;9:19. doi: 10.1186/s13071-016-1298-7.

14.

Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.

Rozati S, Cheng PF, Widmer DS, Fujii K, Levesque MP, Dummer R.

Clin Cancer Res. 2016 Apr 15;22(8):2020-31. doi: 10.1158/1078-0432.CCR-15-1435. Epub 2015 Dec 9.

15.

Oxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseases.

Sundar IK, Yao H, Rahman I.

Antioxid Redox Signal. 2013 May 20;18(15):1956-71. doi: 10.1089/ars.2012.4863. Epub 2012 Nov 6. Review.

16.

Digging deep into "dirty" drugs - modulation of the methylation machinery.

Pleyer L, Greil R.

Drug Metab Rev. 2015 May;47(2):252-79. doi: 10.3109/03602532.2014.995379. Epub 2015 Jan 8. Review.

18.

Changes in histone methylation and acetylation during microspore reprogramming to embryogenesis occur concomitantly with Bn HKMT and Bn HAT expression and are associated with cell totipotency, proliferation, and differentiation in Brassica napus.

Rodríguez-Sanz H, Moreno-Romero J, Solís MT, Köhler C, Risueño MC, Testillano PS.

Cytogenet Genome Res. 2014;143(1-3):209-18. doi: 10.1159/000365261. Epub 2014 Jul 19.

20.

Genome-wide profiling of histone H3 lysine 9 acetylation and dimethylation in Arabidopsis reveals correlation between multiple histone marks and gene expression.

Zhou J, Wang X, He K, Charron JB, Elling AA, Deng XW.

Plant Mol Biol. 2010 Apr;72(6):585-95. doi: 10.1007/s11103-009-9594-7.

PMID:
20054610

Supplemental Content

Support Center